Why different PDB IDs for the same dysregulated protein can lead to inconsistent in-silico predictions and preclinical results
Authors:
- Christopher Busayo OlowosokeCOChristopher Busayo Olowosoke
- Richmore Chiamaka IbehRIRichmore Chiamaka Ibeh
- Tope Abraham IbisanmiTITope Abraham Ibisanmi
- Prosper Obed ChukwuemekaPCProsper Obed Chukwuemeka
Open Access
- 10 October 2025
- journal article
- Published by Elsevier in In Silico Research in Biomedicine
- Vol. 1
Abstract
No abstract availableThis publication has 67 references indexed in Scilit:
- Discovery of reversible and covalent TEAD 1 selective inhibitors MSC-1254 and MSC-5046 based on one scaffoldBioorganic & Medicinal Chemistry Letters, 2024
- An outlook on structural biology after A lpha F old: tools, limits and perspectivesFEBS Open Bio, 2024
- Computational insights into NIMA-related kinase 6: unraveling mutational effects on structure and functionMolecular and Cellular Biochemistry, 2023
- Machine Learning in Drug Discovery: A ReviewArtificial Intelligence Review, 2021
- Beyond history and “on a roll”: The list of the most well‐studied human protein structures and overall trends in the protein data bankProtein Science, 2021
- Computational modelling of drug delivery to solid tumour: Understanding the interplay between chemotherapeutics and biological system for optimised delivery systemsAdvanced Drug Delivery Reviews, 2018
- Using PyMOL as a platform for computational drug designWIREs Computational Molecular Science, 2017
- Computational approaches for predicting mutant protein stabilityJournal of Computer-Aided Molecular Design, 2016
- Managing risks in drug discovery: reproducibility of published findingsNaunyn-Schmiedeberg's Archives of Pharmacology, 2016
- VMD: Visual molecular dynamicsJournal of Molecular Graphics, 1996